Why pre-screen longevity strategists before the interview
The gap between what is shown in mice and what is shown in humans is the whole issue in this field, and it is routinely skipped over in conversation and in fundraising. Strategists worth hiring are precise about which claims have clinical evidence behind them and which are hypotheses. A short screen asks what the evidence does not yet support, which almost nobody volunteers unprompted.
What actually matters when screening Longevity Research Strategist candidates
- 01
Theoretical command
Check command of the hallmarks of aging framework, epigenetic clocks (Horvath, GrimAge, DunedinPACE), Gompertz mortality modelling, and where senolytic or partial reprogramming evidence actually stands.
- 02
From theory to hardware or code
Probe translation work: intervention roadmaps, ITP or Dog Aging Project data they modelled, trial design input, portfolio theses, or forecasting code they built in Python or R.
- 03
Research judgement
Assess how they weigh hype against evidence: dismissing or backing rapamycin, plasma dilution, yamanaka factor reprogramming, and how they decide which bets deserve capital or attention.
- 04
Explaining it to non-specialists
Test how they brief funders, regulators, or press without overselling immortality: explaining actuarial escape velocity, biomarker surrogacy, or FDA aging-indication hurdles to non-biologists.
Pre-screening questions to ask Longevity Research Strategist candidates
12 questions grouped by what they test. Ask the same set in every screen and score answers on a consistent scale, or send them as an async video screen and compare answers side by side.
Programmes they worked on
3 questions01Can you describe projects you have been involved in relating to ageing research?
Listen forSpecific programmes with their own contribution stated, and the stage the work actually reached.
Involvement described as following the field, or projects described without naming their stage.
02What experience do you have with technologies aimed at extending healthy lifespan?
Listen forIntervention classes discussed with their current evidence base stated accurately for each one.
Interventions described with equal confidence, or preclinical work presented as established.
03Can you discuss partnerships or collaborations with research institutions?
Listen forReal collaborations with named institutions, and their role in establishing or running them.
Relationships described loosely, or collaborations claimed with no output to point at.
Held to evidence
3 questions04How do you measure the effectiveness of clinical interventions in this area?
Listen forClinical endpoints distinguished from biomarkers, with the difficulty of measuring lifespan acknowledged directly.
Biomarker changes treated as proof of effect, or ageing clocks presented as validated endpoints.
05Can you describe your experience with data analysis in biological research?
Listen forStudy design and statistics understood well enough to judge whether a published result is convincing.
Results accepted from abstracts, or no ability to assess sample size and effect size.
06How do you quantify the success of a research strategy?
Listen forMilestones tied to evidence generated rather than papers published or funding raised.
Success measured by publications or investment, with no scientific milestone attached.
Priorities by tractability
3 questions07How do you prioritise different research avenues when setting a strategy?
Listen forPrioritisation on tractability and time to evidence, with promising areas deliberately deprioritised.
Everything pursued in parallel, or priority driven by which area attracts the most attention.
08How do you balance short-term results against long-term research goals?
Listen forNear-term evidence that de-risks the longer programme, with a clear view of what would stop a line of work.
No criteria for abandoning a research direction, or short-term work with no bearing on the long goal.
09How do you approach risk in the context of experimental interventions?
Listen forTrial oversight and participant safety treated as non-negotiable, with regulated pathways followed properly.
Interest in unregulated self-experimentation, or trial oversight described as an obstacle.
Honest communication
3 questions10What is your understanding of the ethical considerations in this field?
Listen forAccess, equity and participant welfare all considered, with the hype problem in this field acknowledged.
Ethics answered as regulation, or no acknowledgement of overclaiming as a problem in the field.
11How do you engage with investors, researchers and the public about progress?
Listen forUncertainty retained when speaking publicly, with the same caveats given to investors as to scientists.
Different confidence levels for different audiences, or timelines given for human outcomes.
12How do you handle confidential information and intellectual property in research?
Listen forConfidentiality respected across all collaborators, with publication and patent protection balanced deliberately.
Collaborator material discussed loosely, or no process for handling pre-publication data.
How to score responses
Score every candidate on the same four criteria immediately after the screen. At this stage you are shortlisting for panel interviews, not making the final call.
Theoretical command
35%5Cites specific intervention classes and clock validation limits, distinguishes lifespan from healthspan data, and names where the mouse-to-human gap breaks.
From theory to hardware or code
30%5Shows a concrete artefact, for example a modelled LEV timeline, a biotech landscape map, or a funding thesis that shaped real allocation decisions.
Research judgement
20%5Names claims they revised after new data, separates mechanism plausibility from clinical evidence, and states falsifiable conditions for their own forecasts.
Explaining it to non-specialists
15%5Translates escape velocity maths into plain scenarios with explicit uncertainty, and resists the sensational framing journalists and investors push for.
The gap between mouse data and human outcomes is the whole issue, and it gets skipped. A one-way video screen asks what is not yet supported.
Try it on HirevireScreening FAQ
Process basics
How long should a pre-screening round for this role take?
Fifteen minutes across eight to ten questions, answered async. Enough to establish programmes they worked on, test how they handle evidence, and hear how they communicate publicly.
How scientific does this role need to be?
Enough to read a trial and judge it. A strategist who cannot assess study design will fund work on the strength of a press release and defend it afterwards.
Evaluating answers
What is the strongest signal when screening this role?
Naming what the evidence does not support. Strategists with scientific discipline distinguish mouse data, biomarkers and clinical endpoints. Anyone describing the whole field with equal confidence is repeating a narrative.
What should worry me in an answer?
Confident timelines for human outcomes, or biomarker changes presented as evidence of life extension. Both indicate someone who will make claims your organisation cannot substantiate later.
Go deeper on this role
Sanat has been hiring since 2012 and watching the recruitment industry change up close ever since, and turned that screening process into Hirevire's video screening platform. LinkedIn
